Simon Peter Cooper - 21 Jan 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Medical Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
21 Jan 2022
Net transactions value
$0
Form type
4
Filing time
25 Jan 2022, 15:12:21 UTC
Previous filing
11 Aug 2021
Next filing
17 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Award $0 +50,000 $0.000000 50,000 21 Jan 2022 Common Stock 50,000 $46.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth (1/4th) of the shares subject to the option shall vest on January 19, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.